What are the dosing recommendations, contraindications, and common adverse effects of atomoxetine for treating ADHD?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Atomoxetine for ADHD: Dosing, Contraindications, and Adverse Effects

Dosing Recommendations

Start atomoxetine at 0.5 mg/kg/day in children and adolescents up to 70 kg, titrate to a target of 1.2 mg/kg/day (maximum 1.4 mg/kg/day); for those over 70 kg and adults, start at 40 mg/day, target 80 mg/day (maximum 100 mg/day). 1

Pediatric Dosing Algorithm:

  • Children/adolescents ≤70 kg:

    • Initial: 0.5 mg/kg/day
    • Target: 1.2 mg/kg/day after minimum 3 days
    • Maximum: 1.4 mg/kg/day
  • Children/adolescents >70 kg and adults:

    • Initial: 40 mg/day
    • Target: 80 mg/day after minimum 3 days
    • Maximum: 100 mg/day

Critical Dosing Adjustments:

Reduce dose by 50% in patients taking strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine), those with moderate hepatic impairment, or known CYP2D6 poor metabolizers; reduce by 75% in severe hepatic impairment. 1 This is essential because poor metabolizers have 10-fold higher plasma concentrations and slower elimination 2.

Dosing Pitfalls:

Real-world data shows atomoxetine is frequently underdosed at approximately 60 mg/day in adults when 80 mg/day is the recommended target 3. Maintain patients at target dose for 4-6 weeks before judging efficacy 3. The 2026 dose-response meta-analysis demonstrates that doubling the atomoxetine dose approximately doubles the treatment effect in children and adolescents 4.

Atomoxetine can be given once daily (morning) or divided into two equal doses; once-daily dosing maintains efficacy into the evening 2.


Contraindications

Absolute Contraindications 1:

  1. Hypersensitivity to atomoxetine or product constituents
  2. MAOI use within 2 weeks (or other drugs affecting brain monoamine concentrations)
  3. Narrow-angle glaucoma
  4. Pheochromocytoma or history thereof
  5. Severe cardiovascular disorders that might deteriorate with clinically important increases in heart rate and blood pressure

Relative Contraindications/Cautions:

  • Structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities: Atomoxetine generally should not be used in children/adolescents with these conditions; consider not using in adults with clinically significant cardiac abnormalities 1
  • Hypertension, tachycardia, cardiovascular/cerebrovascular disease: Use with extreme caution 1
  • Bipolar disorder: Screen patients before initiating treatment 5, 1

Common Adverse Effects

Children and Adolescents (≥5% and ≥2× placebo) 5, 1:

  • Nausea (10% vs 5% placebo)
  • Vomiting (11% vs 6% placebo)
  • Fatigue (8% vs 3% placebo)
  • Decreased appetite (16% vs 4% placebo)
  • Abdominal pain (18% vs 10% placebo)
  • Somnolence (11% vs 4% placebo)

Adults (≥5% and ≥2× placebo) 5:

  • Constipation
  • Dry mouth
  • Nausea
  • Fatigue
  • Decreased appetite
  • Dizziness
  • Erectile dysfunction
  • Urinary hesitation

Cardiovascular Effects:

Atomoxetine increases heart rate by 1-2 bpm and blood pressure by 1-4 mmHg on average 5. However, 5-10% of patients experience potentially clinically important changes (≥20 bpm heart rate increase or ≥15-20 mmHg blood pressure increase) 1. Monitor vital signs regularly.

Serious Adverse Effects:

BLACK BOX WARNING: Increased risk of suicidal ideation in children and adolescents 1. Monitor closely for suicidality, clinical worsening, and unusual behavioral changes, particularly when initiating treatment 5, 1.

  • Severe liver injury: Discontinue immediately if jaundice or laboratory evidence of liver injury occurs; do not restart 1. Extremely rare but serious 2
  • Growth effects: Initial height/weight delays in first 1-2 years, typically returns to expected trajectory after 2-3 years 5
  • Priapism: Requires prompt medical attention 1
  • Urinary retention/hesitancy: Monitor for effects on urine outflow 1
  • Allergic reactions: Including anaphylaxis, angioedema, urticaria, rash 1

CYP2D6 Poor Metabolizer-Specific Effects:

Poor metabolizers (approximately 7% of Caucasians) experience higher rates of: insomnia (11% vs 6%), weight decrease (7% vs 4%), constipation (7% vs 4%), depression (7% vs 4%), tremor (5% vs 1%), and syncope (3% vs 1%) 1.

Discontinuation Rates:

In acute pediatric trials, 3% discontinued due to adverse events (vs 1.4% placebo); 6.3% of extensive metabolizers and 11.2% of poor metabolizers discontinued in all studies 1. The 2026 meta-analysis found maximum discontinuation risk of 3.6% at approximately 60 mg/day (vs 1.3% placebo), with no clear dose-dependent risk observed for atomoxetine 4.


Key Clinical Considerations

Obtain cardiac history (personal and family) before initiating treatment: Screen for sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome. If risk factors present, obtain ECG and consider cardiology referral 5.

Taper when discontinuing: Unlike stimulants, atomoxetine discontinuation is generally well tolerated with low incidence of discontinuation-emergent adverse events 2, but gradual tapering is prudent.

Efficacy timeline: The 2026 network meta-analysis confirms atomoxetine is significantly less effective than extended-release methylphenidate (OROS) and extended-release mixed amphetamine salts, but comparable to immediate-release methylphenidate 4, 2.

Advantages over stimulants: No abuse potential, not a controlled substance, useful for patients with comorbid anxiety, tics, or substance abuse risk 2, 6. Atomoxetine appears less likely than methylphenidate to exacerbate sleep disorders 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.